Advanced Search

Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 1999 September;47(9) > Minerva Cardioangiologica 1999 September;47(9):275-84

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752

Frequency: Bi-Monthly

ISSN 0026-4725

Online ISSN 1827-1618

 

Minerva Cardioangiologica 1999 September;47(9):275-84

    ORIGINAL ARTICLES

Bovine pericardial bioprosthesis in mitral position. A ten-year follow-up

Actis Dato G. M., Caimmi P., Aidala E., Bardi G., Trichiolo S., Flocco R., Trimboli S., Di Summa M., Poletti G.

Background. The pericardial bovine prosthesis Pericarbon should offer some advantages in comparison with the former generations, because its development is focused on solving previous problems and resulted in the variation of the pericardial fixation method, of valve structure and of stent coating. This hypothesis was evaluated through a retrospective follow-up.
Methods. Between 1985 and 1989, 78 Pericar-bon prostheses Ø 29 were implanted in mitral position by the same surgeon. All patients received warfarin for the first three months to mantain an International Normalized Ratio between 2.5 and 3.5; after which they received antiaggregant therapy indefinitely. With an average follow-up period of 7.34 years for a total of 573 patient-years, we evaluated perioperative and late mortality, late morbidity (thromboembolic and haemorrhagic events, reoperations, primary tissue failures, endocarditic events) and patient clinical conditions.
Results. Perioperative mortality was 1.28% (1/78), late mortality was 11.6% (9/77) with 5 valve-related deaths. 5-year survival was 93% and 10-year survival 97%. Fifteen patients required reoperation for prosthetic replacement, fourteen for primary tissue failure. There were ten minor thromboembolic events, one major event, one haemorrhage and one prosthetic endocarditis (the last two with patient exitus). After 10 years 75% of patients were in New York Heart Association class I-II.
Conclusions. Besides the known better haemodynamic performance, Pericarbon bioprosthesis seems to present a survival and redo-freedom curve comparable to the best porcine prosthesis, with less incidence of endocarditis, thromboembolic events and prosthesis leakage.

language: English, Italian


FULL TEXT  REPRINTS

top of page